




HEROIN




Past 6 month use of heroin decreased to 23% in the 2021 sample (47% in 2020).



Of those who had recently consumed heroin, 45% used it weekly or more often, stable from 72% in 2020.




The median reported price for a point of heroin was \$100 in 2021 and \$100 in 2020.




Of those who could comment 78% perceived heroin to be 'easy' or 'very easy' to obtain, stable from 60% in 2020.


METHAMPHETAMINE




Past 6 month use of any (88%), crystal (83%), and powder (34%) methamphetamine remained stable in 2021, whereas base decreased (n≤5).



Of those who had recently used any form of methamphetamine, 81% used it at least weekly, stable from 83% in 2020.



The median reported price for a point of crystal methamphetamine was \$50 in 2021, a decrease from \$75 in 2020.



Of those who could comment, 93% perceived crystal methamphetamine to be 'easy' or 'very easy' to obtain in 2021, an increase from 80% in 2020.


OTHER DRUGS

Non-prescribed morphine



Past 6 month use of non-prescribed morphine was stable at 10% in the 2020 sample and 8% in 2021.

Non-prescribed fentanyl



Past 6 month use of non-prescribed fentanyl was stable at 10% in the 2020 sample and 6% in 2021.

Non-prescribed pregabalin




Past 6 month use of non-prescribed pregabalin was stable at 6% in the 2020 sample and 7% in 2021.

GHB/GBL/1,4-BD




Past 6 month use of GHB/GBL/1,4-BD decreased from 23% in the 2020 sample to 9% in 2021.


CANNABIS




Past 6 month use of any cannabis was stable at 67% in both the 2020 and 2021 samples.



Of those who had consumed cannabis recently, three-fifths reported daily use (60%).



Of people who had consumed cannabis in the last 6 months, 94% had smoked it.




Of those who could comment 94% perceived hydro and 82% perceived bush to be 'easy' or 'very easy' to obtain.


2021 SAMPLE CHARACTERISTICS




In 2021, 101 people from Adelaide, SA participated in IDRS interviews.



The mean age in 2021 was 45, and 57% identified as male.




In the 2021 sample, 88% were unemployed and 15% had no fixed address.




Participants were recruited on the basis that they had injected drugs at least monthly in the previous 6 months.


INJECTING RELATED RISKS AND HARMS



In 2021, n≤5 of the IDRS sample reported receptive needle sharing, and 7% reported distributive needle sharing.



The number of people who re-used their own needles decreased from 54% in 2020 to 39% 2021.




In the SA sample, 35% of participants reported injecting someone else after injecting themselves.




In 2021, 29% of the SA sample reported having an injection-related health issue in the month preceding interview.


OTHER HARMS AND HELP-SEEKING




IDRS participants' use of drugs the day before interview participation, 2021.



In the 2021 sample, 14% had experienced a non-fatal overdose in the previous 12 months and 24% were currently in drug treatment.




In the sample, 49% self reported a mental health problem in the six months prior to interview, and 31% had seen a mental health professional.




Of those who commented, the three most common mental health issues reported were depression (65%), anxiety (54%) and PTSD (25%).


NALOXONE AND HARM REDUCTION



IDRS participants' knowledge of the take-home naloxone program remained stable in 2021 whereas participation in training increased.



Of those who reported having heard of naloxone, 17% had used naloxone to resuscitate someone who had overdosed.



Of those who reported ever accessing naloxone, 41% received intramuscular naloxone, 59% intranasal naloxone and 0% both.



In 2021, n≤5 of the sample reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.